Benjamin T Himes
Overview
Explore the profile of Benjamin T Himes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
438
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Riviere-Cazaux C, Graser C, Warrington A, Hoplin M, Andersen K, Malik N, et al.
Neuro Oncol
. 2025 Jan;
PMID: 39786485
Background: While serial sampling of glioma tissue is rarely performed prior to recurrence, cerebrospinal fluid (CSF) is an underutilized longitudinal source of candidate glioma biomarkers for understanding therapeutic impacts. However,...
2.
Inocencio J, Mitrasinovic S, Asad M, Parney I, Zang X, Himes B
Front Immunol
. 2024 Sep;
15:1424396.
PMID: 39346924
Immune checkpoint (IC) inhibition in glioblastoma (GBM) has not shown promising results in the last decade compared to other solid tumors. Several factors contributing to the lack of immunotherapy response...
3.
Riviere-Cazaux C, Graser C, Warrington A, Hoplin M, Andersen K, Malik N, et al.
medRxiv
. 2024 May;
PMID: 38798641
One Sentence Summary: Glioma cerebrospinal fluid (CSF) accessed intra-operatively and longitudinally via devices can reveal impacts of treatment and anatomical location.
4.
Riviere-Cazaux C, Rajani K, Rahman M, Oh J, Brown D, White J, et al.
Fluids Barriers CNS
. 2023 Dec;
20(1):94.
PMID: 38115038
Background: Microdialysis is a technique that can be utilized to sample the interstitial fluid of the central nervous system (CNS), including in primary malignant brain tumors known as gliomas. Gliomas...
5.
Blood-brain barrier disruption defines the extracellular metabolome of live human high-grade gliomas
Riviere-Cazaux C, Carlstrom L, Rajani K, Munoz-Casabella A, Rahman M, Gharibi-Loron A, et al.
Commun Biol
. 2023 Jun;
6(1):653.
PMID: 37340056
The extracellular microenvironment modulates glioma behaviour. It remains unknown if blood-brain barrier disruption merely reflects or functionally supports glioma aggressiveness. We utilised intra-operative microdialysis to sample the extracellular metabolome of...
6.
Tritz Z, Ayasoufi K, Wolf D, Owens C, Malo C, Himes B, et al.
Cancer Immunol Res
. 2023 Mar;
11(6):763-776.
PMID: 36921098
Glioblastoma (GBM) is the most common malignant brain tumor in adults, responsible for approximately 225,000 deaths per year. Despite preclinical successes, most interventions have failed to extend patient survival by...
7.
Kerezoudis P, Kerezoudi E, Choudhry A, Himes B, Parney I
Neurosurgery
. 2023 Jan;
92(3):464-471.
PMID: 36650046
Background: Many patients with glioma and their caregivers seek complementary and alternative medicine (CAM) methods to comfort themselves, cope with cancer medication side effects, and feel they are taking control...
8.
Himes B, Fain C, Tritz Z, Nesvick C, Jin-Lee H, Geiger P, et al.
J Neurosurg
. 2022 Sep;
138(5):1291-1301.
PMID: 36115048
Objective: The profound immunosuppression found in glioblastoma (GBM) patients is a critical barrier to effective immunotherapy. Multiple mechanisms of tumor-mediated immune suppression exist, and the induction of immunosuppressive monocytes such...
9.
Jung M, Aibaidula A, Brown D, Himes B, Cumba Garcia L, Parney I
Neurooncol Adv
. 2022 Aug;
4(1):vdac017.
PMID: 35990703
Background: Glioblastoma (GBM), the most common primary brain tumor, has a median survival of 15-16 months. Immunotherapy is promising but GBM-mediated immunosuppression remains a barrier. GBMs express the interferon-gamma (IFN-γ)-responsive...
10.
Liu J, Wang X, Chen A, Gao X, Himes B, Zhang H, et al.
Nat Commun
. 2022 Apr;
13(1):2196.
PMID: 35459228
Glioblastoma (GBM) is a deadly disease without effective treatment. Because glioblastoma stem cells (GSCs) contribute to tumor resistance and recurrence, improved treatment of GBM can be achieved by eliminating GSCs...